Cargando…

Identification of BIRC6 as a novel intervention target for neuroblastoma therapy

BACKGROUND: Neuroblastoma are pediatric tumors of the sympathetic nervous system with a poor prognosis. Apoptosis is often deregulated in cancer cells, but only a few defects in apoptotic routes have been identified in neuroblastoma. METHODS: Here we investigated genomic aberrations affecting genes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamers, Fieke, Schild, Linda, Koster, Jan, Speleman, Frank, Øra, Ingrid, Westerhout, Ellen M, van Sluis, Peter, Versteeg, Rogier, Caron, Huib N, Molenaar, Jan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495678/ https://www.ncbi.nlm.nih.gov/pubmed/22788920 http://dx.doi.org/10.1186/1471-2407-12-285

Ejemplares similares

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells
por: Dolman, M. Emmy M., et al.
Publicado: (2015)

A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients
por: Fardin, Paolo, et al.
Publicado: (2010)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma
por: van Groningen, Tim, et al.
Publicado: (2019)

Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
por: van Wezel, Esther M., et al.
Publicado: (2019)

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma
por: Olsen, Thale Kristin, et al.
Publicado: (2022)

Intratumour Diversity of Chromosome Copy Numbers in Neuroblastoma Mediated by On-Going Chromosome Loss from a Polyploid State
por: Lundberg, Gisela, et al.
Publicado: (2013)

Modulation of Neuroblastoma Disease Pathogenesis By An Extensive Network of Epigenetically Regulated MicroRNAs
por: Das, Sudipto, et al.
Publicado: (2012)

Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma
por: van den Boogaard, Marlinde L., et al.
Publicado: (2021)

Meta-mining of copy number profiles of high-risk neuroblastoma tumors
por: Depuydt, Pauline, et al.
Publicado: (2018)

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism
por: Mandriota, Stefano J., et al.
Publicado: (2015)

BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
por: Frazzi, Raffaele
Publicado: (2021)

Two opposing gene expression patterns within ATRX aberrant neuroblastoma
por: van Gerven, Michael R., et al.
Publicado: (2023)

Prevalence of congenital heart defects in neuroblastoma patients: a cohort study and systematic review of literature
por: van Engelen, Klaartje, et al.
Publicado: (2008)

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
por: Bleeker, Gitta, et al.
Publicado: (2014)

Differential regulation of BIRC2 and BIRC3 expression by inflammatory cytokines and glucocorticoids in pulmonary epithelial cells
por: Thorne, Andrew, et al.
Publicado: (2023)

CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients
por: Rihani, Ali, et al.
Publicado: (2014)

Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome
por: Schramm, A, et al.
Publicado: (2012)

Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential
por: Yamato, Azusa, et al.
Publicado: (2015)

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features
por: Kool, Marcel, et al.
Publicado: (2008)

SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry
por: Decaesteker, Bieke, et al.
Publicado: (2023)

Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
por: van Gerven, Michael R., et al.
Publicado: (2022)

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

Increased Expression of BIRC2, BIRC3, and BIRC5 from the IAP Family in Mesenchymal Stem Cells of the Umbilical Cord Wharton's Jelly (WJSC) in Younger Women Giving Birth Naturally
por: Gil-Kulik, Paulina, et al.
Publicado: (2020)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2015)

Bioinformatics analysis of BIRC5 in human cancers
por: Ye, Han-Bin, et al.
Publicado: (2022)

Gene Network Revealed Involvements of Birc2, Birc3 and Tnfrsf1a in Anti-Apoptosis of Injured Peripheral Nerves
por: Wang, Yongjun, et al.
Publicado: (2012)

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets
por: Decaesteker, Bieke, et al.
Publicado: (2018)

BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia
por: Roohollahi, Khashayar, et al.
Publicado: (2022)

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017)

BIRC6 Is Associated with Vulnerability of Carotid Atherosclerotic Plaque
por: Alloza, Iraide, et al.
Publicado: (2020)

BIRC7 is Beneficial for Melanoma Progression and Hypoxic Response
por: Xu, Haiting, et al.
Publicado: (2022)

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma
por: Cuperus, Roos, et al.
Publicado: (2009)

Identification of ARNT-regulated BIRC3 as the target factor in cadmium renal toxicity
por: Lee, Jin-Yong, et al.
Publicado: (2017)

Joint Binding of OTX2 and MYC in Promotor Regions Is Associated with High Gene Expression in Medulloblastoma
por: Bunt, Jens, et al.
Publicado: (2011)

N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance
por: Lammens, Tim, et al.
Publicado: (2012)

Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies
por: M. Kholosy, Waleed, et al.
Publicado: (2021)

Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas
por: Gisselsson, David, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5o734u774gja9f76i8t8rjvl73